An Observational Study Comparing Delandistrogene Moxeparvovec With Standard of Care in Participants With Duchenne Muscular Dystrophy

Recruiting

An Observational Study Comparing Delandistrogene Moxeparvovec With Standard of Care in Participants With Duchenne Muscular Dystrophy

Sponsor:

Sarepta Therapeutics, Inc.

Code:

NCT06270719

Conditions

Duchenne Muscular Dystrophy

Eligibility Criteria

Sex: Male

Age: 4+

Healthy Volunteers: Not accepted

Interventions

Delandistrogene Moxeparvovec

Standard of Care

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-15. This information was provided to ClinicalTrials.gov by Sarepta Therapeutics, Inc. on 2025-05-02.